
Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideo
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Scroll To Top
By continuing to use our site, you agree to our Private Policy and Terms of Use.
An aggressive approach toward lowering cardiovascular risk factors among HIVers--including one or more lipid-lowering medications, antiplatelet therapies, and changing from other protease inhibitors to Reyataz, which has less impact on lipid levels--achieves much greater reductions in "bad" LDL cholesterol levels than a more standard approach, according to a study presented at the 2009 IAS Conference. After 12 months of aggressive treatment, study subjects' mean LDL cholesterol levels dropped by nearly 38%, and decreases in blood-based levels of C-reactive protein, a biomarker for heart disease, also were recorded. LDL levels decreased by only about 4% and biomarker levels rose slightly among those in the standard-approach arm. The researchers are now reviewing data from a three-year study of the HIVers to gauge the long-term effects of aggressive treatment.
From our Sponsors
Most Popular
Plus: Featured Video